Krivic et al., 2008) (i.e., after the Achilles tendon transection and detachment from calcaneal bone), or ligament healing (Figure 11), BPC 157 counteracts muscle disability related to various noxious procedures, after abdominal aorta anastomosis (Hrelec et al., 2009), L2-L3 compression (Perovic et al., 2019), severe electrolytes disturbances (Medvidovic-Grubisic et al., 2017), application of the succinylcholine (Stambolija et al., 2016), neuroleptics (Jelovac et al., 1999
No claims regarding human therapeutic outcomes are made or implied
This includes your doctors, nurses, pharmacists, and dentists
As of April 2026, no FDA communication formally distinguishes PDA from BPC-157
AIPAK engineering presents authentic information about this topic
Scientists call it a cytoprotective peptide, meaning it is tested for its ability to shield cells from damage